<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Aug. 2, 2018 (HealthDay News) — The C-509T allele in the promoter region of transforming growth factor \u03b2 (TGFB1<\/i>) is associated with radiation-induced breast fibrosis risk among patients with early-stage breast cancer, according to study published online July 19 in JAMA Oncology<\/i>.<\/p>\n
Aaron J. Grossberg, M.D., Ph.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues examined the correlation between the C-509T variant allele in the promoter region of TGFB1<\/i> and breast fibrosis three years after radiotherapy in a cohort study nested in an open-label, randomized clinical trial that compared hypofractionated whole-breast irradiation (WBI) with conventionally fractionated WBI. Two hundred eighty-seven women aged 40 years or older with pathologically confirmed stage 0 to IIA breast cancer treated with breast-conserving surgery were enrolled and observed for a minimum of three years.<\/p>\n
TGFB1<\/i> genotype and three-year radiotherapy-induced toxicity data were available for 174 patients, 51 percent of whom had at least one copy of C-509T. The researchers found that 13.8 percent of patients with C-509T and 3.8 percent of those without the allele variant had grade 2 or higher breast fibrosis. In multivariable analysis, the only factors significantly associated with breast fibrosis risk were C-509T and postoperative cosmetic outcomes (odds ratios, 4.47 and 7.09, respectively).<\/p>\n
“The C-509T allele in TGFB1<\/i> is a key determinant of breast fibrosis risk,” the authors write. “Assessing TGFB1<\/i> genotype may facilitate a more personalized approach to locoregional treatment decisions in breast cancer.”<\/p>\n
Two authors disclosed financial ties to the pharmaceutical and medical device industries.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n